Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19

OBJECTIVE: Lopinavir/ritonavir (LPV/RTV) exposure is decreased in children after crushing the tablets. Whether exposure is also decreased in adult patients is not known. This study evaluated the exposure of LPV/RTV in adult patients after administration of crushed LPV/RTV tablets. METHODS: Blood sam...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohsenian Naghani, Shaghayegh, Jansen, Mark MPM, Jaspers, Tessa, Bastiaans, Diane, Burger, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086723/
https://www.ncbi.nlm.nih.gov/pubmed/33990390
http://dx.doi.org/10.1136/ejhpharm-2020-002596
_version_ 1785022207645188096
author Mohsenian Naghani, Shaghayegh
Jansen, Mark MPM
Jaspers, Tessa
Bastiaans, Diane
Burger, David
author_facet Mohsenian Naghani, Shaghayegh
Jansen, Mark MPM
Jaspers, Tessa
Bastiaans, Diane
Burger, David
author_sort Mohsenian Naghani, Shaghayegh
collection PubMed
description OBJECTIVE: Lopinavir/ritonavir (LPV/RTV) exposure is decreased in children after crushing the tablets. Whether exposure is also decreased in adult patients is not known. This study evaluated the exposure of LPV/RTV in adult patients after administration of crushed LPV/RTV tablets. METHODS: Blood samples were drawn from patients with COVID-19 who were receiving crushed LPV/RTV 400/100 mg tablets twice daily. RESULTS: Plasma concentrations for 11 patients with COVID-19 (eight men, mean age 62.6 years) were included. The measured plasma concentrations of LPV were substantially higher than reported for patients with HIV. CONCLUSIONS: There is adequate exposure from crushed LPV/RTV tablets, but because of limited experience, therapeutic drug monitoring is still advised.
format Online
Article
Text
id pubmed-10086723
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-100867232023-04-12 Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19 Mohsenian Naghani, Shaghayegh Jansen, Mark MPM Jaspers, Tessa Bastiaans, Diane Burger, David Eur J Hosp Pharm Short Report OBJECTIVE: Lopinavir/ritonavir (LPV/RTV) exposure is decreased in children after crushing the tablets. Whether exposure is also decreased in adult patients is not known. This study evaluated the exposure of LPV/RTV in adult patients after administration of crushed LPV/RTV tablets. METHODS: Blood samples were drawn from patients with COVID-19 who were receiving crushed LPV/RTV 400/100 mg tablets twice daily. RESULTS: Plasma concentrations for 11 patients with COVID-19 (eight men, mean age 62.6 years) were included. The measured plasma concentrations of LPV were substantially higher than reported for patients with HIV. CONCLUSIONS: There is adequate exposure from crushed LPV/RTV tablets, but because of limited experience, therapeutic drug monitoring is still advised. BMJ Publishing Group 2023-03 2021-05-14 /pmc/articles/PMC10086723/ /pubmed/33990390 http://dx.doi.org/10.1136/ejhpharm-2020-002596 Text en © European Association of Hospital Pharmacists 2023. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Short Report
Mohsenian Naghani, Shaghayegh
Jansen, Mark MPM
Jaspers, Tessa
Bastiaans, Diane
Burger, David
Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
title Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
title_full Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
title_fullStr Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
title_full_unstemmed Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
title_short Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
title_sort crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with covid-19
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086723/
https://www.ncbi.nlm.nih.gov/pubmed/33990390
http://dx.doi.org/10.1136/ejhpharm-2020-002596
work_keys_str_mv AT mohseniannaghanishaghayegh crushinglopinavirritonavirtabletsdoesnotresultinlowerexposuretolopinavirritonavirinadultpatientswithcovid19
AT jansenmarkmpm crushinglopinavirritonavirtabletsdoesnotresultinlowerexposuretolopinavirritonavirinadultpatientswithcovid19
AT jasperstessa crushinglopinavirritonavirtabletsdoesnotresultinlowerexposuretolopinavirritonavirinadultpatientswithcovid19
AT bastiaansdiane crushinglopinavirritonavirtabletsdoesnotresultinlowerexposuretolopinavirritonavirinadultpatientswithcovid19
AT burgerdavid crushinglopinavirritonavirtabletsdoesnotresultinlowerexposuretolopinavirritonavirinadultpatientswithcovid19

Ejemplares similares